Patiromer 

Patiromer is an orally active, selective and non-absorbable intestinal potassium (K⁺) polymer binder that reversibly binds potassium ions in exchange for calcium (Ca²⁺). Patiromer can rapidly and continuously reduce serum potassium levels, maintain a normal blood potassium state, and reduce serum aldosterone levels. Patiromer also increases fecal potassium excretion. Patiromer is mainly used in the study of hyperkalemia associated with diseases such as chronic kidney disease, diabetes, and heart failure, and is particularly suitable for improving renin-angiotensin-aldosterone system inhibitor (RAASi) therapy^[1][2][3].

Patiromer is a sodium-free, non-absorbable K⁺ binding polymer^[2].
Patiromer has a significantly higher potassium binding capacity in vitro than traditional resins such as polystyrene sulfonate and has high-capacity potassium binding properties^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Patiromer (4 g/kg; oral gavage; once daily; 8 days or 12 weeks) significantly reduces serum K⁺ and aldosterone levels in a unilaterally nephrectomized male spontaneously hypertensive rat model with induced chronic hyperkalemia^[2].

Animal Dosing Preparation:
This product is orally active and is routinely administered via gavage or feed. For gavage administration, due to its poor water solubility, prepare the dosage based on the daily powder requirement and volume for each animal before administration. The specific procedure is as follows:
Weigh the appropriate amount of powder and add an appropriate amount of drinking water. Vortex or stir thoroughly. The powder will not completely dissolve at this point; the system will be a homogeneous suspension. Administer the solution via gavage immediately after preparation. If powder residue remains in the container after administration, add a small amount of pure water, stir well, and administer via gavage again immediately. Repeat this step if necessary to ensure the animal ingests all the powder.
Precautions:
1. The gavage volume must be strictly controlled within a reasonable range. For rats and mice, it is recommended not to exceed 10 mL/kg.
2. This product is poorly soluble in water; the suspension should be used immediately after preparation and should not be stored for extended periods.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

C₂₈H₄₈CaFO₂⁺

1208912-84-8

Solid

White to light yellow

CCC(C([O-])=O)(F)CC(C1=CC=CC=C1)CC(CCCCC(C)CC)C.CC(CC)C.[Ca+2].[p].[p].[n].[m].[n].[1/2]

Room temperature in continental US; may vary elsewhere.

Store at 4°C, do not freeze

• [1]. Weir MR, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med. 2015 Jan 15;372(3):211-21.  [Content Brief]

  [2]. Iyer SPN, et al. Pharmacodynamic effects of the K+ binder patiromer in a novel chronic hyperkalemia model in spontaneously hypertensive rats. Physiol Rep. 2020 Sep;8(18):e14572.  [Content Brief]

  [3]. Colbert GB, et al. Patiromer for the treatment of hyperkalemia. Expert Rev Clin Pharmacol. 2020 Jun;13(6):563-570.  [Content Brief]